Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 12/14/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: November 1, 2018 - November 30, 2018

 

MOR - 1b

Schedule of Debtor Bank Account Balances (1)

For the Period: November 1, 2018 - November 30, 2018

(Unaudited)

 

$ USD ‘000s

Debtor         

  

Bank

   Last Four Digits
Account No.
    

Account Description

   Beginning
Balance
11/1/2018
     Ending
Balance
11/30/2018
 

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      6813      General checking    $ —        $ —    

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      3036      Sweep account      29,148        28,155  

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      7307      Utility adequate assurance(2)      10        —    

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      5177      Collateral      100        100  
           

 

 

    

 

 

 

Total Bank Account Balances

            $ 29,258      $ 28,255  
           

 

 

    

 

 

 

Notes:

 

(1)

The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-1a) represent book balances while MOR-1b represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts.

(2)

The Utility account with Silicon Valley Bank was closed and the entire balance of $10,472 was transferred back to the General checking account. This transfer was completed on 11/12/2018.